RE:RE:RE:Spectral mgnt may requst an extension for a U.S. listingGood reminder
I agree that an extension/renewal to the Reverse Split, is most likely a part of the AGM.
Let's hope they plan on being a bit more promotional for the balance of 2021 in order to help drive the pre-split SP into the $ 1 - $ 2 Cdn range...
And let's hope they therfore expand the range of the RS to something more like, from 1:5 to 1:20.
If they keep it at 1:10 to 1:20 it might indicate we can expect a continuation of the silent treatment for another 6 months or so.
If Spectral plays its cards right on a Dialco spin-out (with IPO?) and a Nasdaq intention announcment, those things, in and of themselves, may get the SP into a more acceptable (pre-split) range. It has worked for other co.s. Keeping some powder dry (e.g final FDA rulings on two key components) for the post listing would not be a bad thing, but I do NOT agree that the application should be made AFTER they know the results of PMX /Tigris and the DIMI Home Study. You want approval news while in THE BIG SHOW. Nothing worse than listing on Nasdaq and not having any more big news to deliver. Besides, a Nasdaq application can take 3 -4 months to execute.
All IMHO.
MM